AstraZeneca PLC (LON:AZN) Receives Average Rating of “Moderate Buy” from Brokerages

AstraZeneca PLC (LON:AZN) has been given a consensus rating of “Moderate Buy” by the nine brokerages that are currently covering the firm, Marketbeat reports. One research analyst has rated the stock with a sell rating, two have issued a hold rating and six have issued a buy rating on the company. The average 1 year price target among brokerages that have issued ratings on the stock in the last year is £104.12 ($131.22).

Several research analysts have commented on the stock. Deutsche Bank Aktiengesellschaft reissued a “hold” rating and set a £110 ($138.63) price target on shares of AstraZeneca in a research note on Tuesday, September 3rd. JPMorgan Chase & Co. reiterated an “overweight” rating and issued a £140 ($176.43) target price on shares of AstraZeneca in a research report on Thursday, November 7th. Shore Capital reissued a “buy” rating on shares of AstraZeneca in a research note on Thursday, November 7th. Finally, Berenberg Bank reaffirmed a “buy” rating and set a £150 ($189.04) price objective on shares of AstraZeneca in a research note on Monday, September 2nd.

Insider Buying and Selling at AstraZeneca

In other AstraZeneca news, insider Pascal Soriot purchased 20,000 shares of the company’s stock in a transaction that occurred on Thursday, November 14th. The stock was bought at an average price of £102.03 ($128.58) per share, with a total value of £2,040,600 ($2,571,644.61). Also, insider Michel Demare acquired 2,000 shares of AstraZeneca stock in a transaction on Friday, September 13th. The shares were bought at an average cost of GBX 118 ($1.49) per share, for a total transaction of £2,360 ($2,974.17). Corporate insiders own 0.04% of the company’s stock.

AstraZeneca Stock Performance

Shares of LON AZN opened at GBX 9,978 ($125.75) on Friday. The stock’s 50-day moving average is £117.03 and its 200 day moving average is £121.32. The stock has a market cap of £154.66 billion, a price-to-earnings ratio of 3,167.62, a P/E/G ratio of 0.86 and a beta of 0.17. AstraZeneca has a 1-year low of GBX 9,461 ($119.23) and a 1-year high of £133.88 ($168.72). The company has a current ratio of 0.89, a quick ratio of 0.59 and a debt-to-equity ratio of 84.97.

AstraZeneca Company Profile

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.